AG-221 (Enasidenib) is a potent, orally available, and selective mutant IDH2 inhibitor. It affects metabolic and epigenetic signaling pathways by reducing 2-HG production and promoting histone demethylation, effectively inducing cell differentiation and inhibiting tumor viability.
AG-221 (Enasidenib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for AG-221 (Enasidenib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- AG-221 (Enasidenib) Mechanism of Action: IDH2 Inhibition in Myeloid Precursor Cell Research
- AG-221 (Enasidenib) Clinical Trials
- AG-221 (Enasidenib): Selectivity & Specificity
- AG-221 (Enasidenib) Working Concentration | Cell Culture | Treatment
- AG-221 (Enasidenib) Solubility in DMSO
- AG-221 (Enasidenib) Stock Solution
- AG-221 (Enasidenib) Storage
- AG-221 (Enasidenib) Stability
- AG-221 (Enasidenib) Combination Database
- AG-221 (Enasidenib) Molecular Weight
- AG-221 (Enasidenib) SMILES
- AG-221 (Enasidenib) CAS Number
- AG-221 (Enasidenib) Chemical Structure (2D and 3D)
- AG-221 (Enasidenib) Sigma (AMBH2D6FEEBB)? Try a better option.
- AG-221 (Enasidenib) Cayman (21277)? Try a better option.
- AG-221 (Enasidenib) MedChemExpress (HY-18690)? Try a better option.
- AG-221 (Enasidenib) SDS｜MSDS